The most common early disappointment on a GLP-1 isn't a side effect. It's the calendar. People expect the medication to work like a switch, and it works more like a dial that gets turned up over months. If you know the real shape of it up front, you're far less likely to decide "this isn't working" at week three.
The first weeks: not much, on purpose
You don't start at a full dose. You start low and step up every few weeks. That's titration, and it gives your gut time to adjust and keeps nausea down (see how titration schedules work). In those early weeks your appetite may barely change, or it may change a lot. Both are normal. The starting dose is mostly about getting used to the medication, so a quiet first month usually means the plan is on schedule.
The realistic rate
In the big trials, average loss was 14.9% of body weight with semaglutide 2.4 mg over 68 weeks (STEP 1), and 15.0% to 20.9% with tirzepatide 5 mg to 15 mg over 72 weeks (SURMOUNT-1). Spread across the whole trial, that comes to roughly 1% of starting weight a month, a little more at the top tirzepatide dose. People in SURMOUNT-1 started at an average of 104.8 kg (about 231 lb), so for them the 15 mg result worked out to about two-thirds of a pound a week. These are averages, and they include the slow titration months and the flattening near the end, so any single month can run faster or slower.
Loss isn't linear either. Some weeks the scale drops, some weeks it doesn't move, and some weeks it ticks up from water or a big meal. None of that means fat has stopped coming off. A trend-smoothing weight app helps you tell a normal blip from a real stall.
Fast responders, slow responders
People respond very differently to the same dose. Fast responders feel their appetite drop hard and early (see what the data say about super responders). Slow responders need a higher dose or more time. Losing slowly doesn't mean you're doing it wrong. It's a reason to talk with your prescriber about the dose or a switch. Before assuming a higher dose is the answer, read does increasing your dose always mean more weight loss?
Switching helps some people, though the data are thin. In one clinic study from Weill Cornell, people who moved from semaglutide to tirzepatide after a plateau lost another 8.1% of body weight over six months. People who had barely responded to semaglutide (under 5% after at least three months) lost 2.9% after switching.
The plateau is coming, and it's normal
At some point the scale stops. As you lose weight, your body gets smaller and burns fewer calories, so the deficit that was driving the loss shrinks until intake and expenditure meet again. A plateau means you've lost real weight. It's a cue to look again at intake, protein, movement or dose, and there's no need to panic.
The part people skip: this is long-term
Obesity behaves like a chronic condition, and these medications treat it while you take them. Stop, and appetite tends to return and weight often comes back. In the STEP 1 extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year (see stopping a GLP-1: tapering, regain, and restarting). That regain is the underlying biology coming back once the drug's signal is gone, and willpower has little to do with it. So plan from the start for a long-term or maintenance treatment, and build the habits that hold the result: protein, strength training and tracking. They help whether you're on a high dose, a maintenance dose, or eventually tapering with your doctor's guidance.
What success looks like
A straight line to a goal weight is rare. Expect a jagged downward trend over many months, a plateau you work through, side effects that ease as you adjust, and habits that hold the loss. Judge it by the trend line over months, and don't read much into any single week on the scale.
Study findings above are attributed to their authors and were located via PubMed.
This is general education, not medical advice. Your timeline, dose, and results are individual — discuss them with your prescriber.